Form 4 for CALC CalciMedica, Inc.
Accepted 2023-03-22 00:00:00 ET · period of report 2023-03-20 · accession 0001209191-23-020682 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-03-22 | 2023-03-20 | CALC | WILSON ROBERT N | Dir | A - Grant | — | +181.7K | 181.7K | New | — |
| DM | 2023-03-22 | 2023-03-20 | CALC | WILSON ROBERT N | Dir | A - Grant | — | +61.3K | 7,577 | New | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-03-20 | A | A | 181,655 | — | 181,655 | D | — | — | (F1) Received in exchange for 6,307,451 shares of common stock of CalciMedica, Inc. ("CalciMedica") pursuant to an Agreement and Plan of Merger and Reorganization (the "Merger Agreement") by and among CalciMedica, the Issuer and Camaro Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub"). Under the terms of the Merger Agreement, on March 20, 2023, Merger Sub merged with and into CalciMedica (the "Merger"), with CalciMedica surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of CalciMedica common stock was converted into the right to receive 0.0288 of a share of the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Graybug Vision, Inc. to CalciMedica, Inc. |
| 2 | Derivative | Director Stock Option (right to buy) | 2023-03-20 | A | A | 5,760 | — | 5,760 | D | $7.99 · — to 2031-06-30 | 5,760 Common Stock | (F7) Received in exchange for a stock option to acquire 200,000 shares of common stock of CalciMedica pursuant to the Merger Agreement. (F3) Upon the closing of the Merger, each outstanding option to purchase shares of CalciMedica common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock. (F6) Beginning on February 22, 2021, the shares subject to the option vest in a series of forty-eight (48) successive equal monthly installments. |
| 3 | Derivative | Director Stock Option (right to buy) | 2023-03-20 | A | A | 5,760 | — | 5,760 | D | $7.99 · — to 2031-04-27 | 5,760 Common Stock | (F7) Received in exchange for a stock option to acquire 200,000 shares of common stock of CalciMedica pursuant to the Merger Agreement. (F3) Upon the closing of the Merger, each outstanding option to purchase shares of CalciMedica common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock. (F6) Beginning on February 22, 2021, the shares subject to the option vest in a series of forty-eight (48) successive equal monthly installments. (F5) Beginning on November 22, 2022, the shares subject to the option vest in a series of twelve (12) successive equal monthly installments. |
| 4 | Derivative | Director Stock Option (right to buy) | 2023-03-20 | A | A | 23,557 | — | 23,557 | D | $6.60 · — to 2030-06-29 | 23,557 Common Stock | (F4) Received in exchange for a stock option to acquire 817,964 shares of common stock of CalciMedica pursuant to the Merger Agreement. (F3) Upon the closing of the Merger, each outstanding option to purchase shares of CalciMedica common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock. (F2) Beginning on June 15, 2020, the shares subject to the option vest in a series of forty-eight (48) successive equal monthly installments. |
| 5 | Derivative | Director Stock Option (right to buy) | 2023-03-20 | A | A | 1,488 | — | 1,488 | D | $17.34 · — to 2033-03-19 | 1,488 Common Stock | (F9) Received in exchange for a stock option to acquire 51,692 shares of common stock of CalciMedica pursuant to the Merger Agreement. (F3) Upon the closing of the Merger, each outstanding option to purchase shares of CalciMedica common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock. (F5) Beginning on November 22, 2022, the shares subject to the option vest in a series of twelve (12) successive equal monthly installments. |
| 6 | Derivative | Warrant | 2023-03-20 | A | A | 8,592 | — | 8,592 | D | $27.94 · — to 2026-02-22 | 8,592 Common Stock | (F11) Received in exchange for a warrant to purchase 298,321 shares of common stock of CalciMedica pursuant to the Merger Agreement. (F10) Immediately exercisable. |
| 7 | Derivative | Warrant | 2023-03-20 | A | A | 8,592 | — | 8,592 | D | $27.94 · — to 2026-06-25 | 8,592 Common Stock | (F11) Received in exchange for a warrant to purchase 298,321 shares of common stock of CalciMedica pursuant to the Merger Agreement. (F10) Immediately exercisable. |
| 8 | Derivative | Director Stock Option (right to buy) | 2023-03-20 | A | A | 7,577 | — | 7,577 | D | $17.34 · — to 2033-03-19 | 7,577 Common Stock | (F8) Received in exchange for a stock option to acquire 263,107 shares of common stock of CalciMedica pursuant to the Merger Agreement. (F3) Upon the closing of the Merger, each outstanding option to purchase shares of CalciMedica common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock. (F5) Beginning on November 22, 2022, the shares subject to the option vest in a series of twelve (12) successive equal monthly installments. |